A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

• Status: Terminated
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the maximum tolerated dose and assess the safety and tolerability of escalating doses of BMS-663513 when given in combination with either radiotherapy alone or radiotherapy plus paclitaxel and carboplatin.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• NSCLC who are eligible to receive a 6 week course of RT

• Part 1 - not candidates for definitive RT

• Part 2 - candidates for definitive RT

Exclusion Criteria:

• Severe COPD, pulmonary infection or interstitial pneumonitis

• Recent cellulitis

• Autoimmune disease